Cingulate Inc (CING)
NASDAQ:CING
Want to see CING full AI Analyst Report?
Top Page
Cingulate Inc
(NASDAQ:CING)
Select Model
Select Model
Rating:47Neutral
Price Target:
$5.00
▼(-8.26% Downside)
Action:Reiterated
Date:05/14/26
The score is held down primarily by weak financial performance (no revenue, recurring losses, leverage concerns, and ongoing cash-burn history) and bearish technicals (below key moving averages with negative MACD). Corporate events provide some support through improved access to capital and governance updates, but that benefit is tempered by dilution risk; valuation metrics offer limited insight due to negative earnings and no dividend.
Positive Factors
Platform-focused lead ADHD program
Cingulate’s concentrated CNS strategy and a platform designed for once-daily delivery create a durable product differentiation in ADHD. A successful clinical outcome could translate into a scalable franchise and licensing appeal across CNS indications, supporting long-term commercialization and partner interest.
Negative Factors
No revenue and persistent net losses
As a clinical-stage biotech with no product sales, Cingulate depends on financing until regulatory approval and commercialization. Multi-year losses of that magnitude increase dilution risk and require sustained access to capital; absent clinical success, profitability remains a distant prospect.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform-focused lead ADHD program
Cingulate’s concentrated CNS strategy and a platform designed for once-daily delivery create a durable product differentiation in ADHD. A successful clinical outcome could translate into a scalable franchise and licensing appeal across CNS indications, supporting long-term commercialization and partner interest.
Read all positive factors
Cingulate Inc (CING) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$60.67M
Dividend YieldN/A
Average Volume (3M)190.99K
Price to Earnings (P/E)―
Beta (1Y)5.29
Revenue GrowthN/A
EPS Growth58.01%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.26
Shares Outstanding13,276,022
10 Day Avg. Volume270,731
30 Day Avg. Volume190,985
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.40
Price to Sales (P/S)0.00
P/FCF Ratio-1.35
Enterprise Value/Market Cap0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit40.73
Enterprise Value/Ebitda-0.28
Forecast
1Y Price Target
$24.33Price Target Upside346.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.92
Revenue Forecast (FY)N/A
Cingulate Inc Business Overview & Revenue Model
Company Description
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), wh...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Cingulate Inc. does not have publicly available information indicating material recurring revenue from commercial product sales. The company’s funding and potential future revenue model is expected to...
Cingulate Inc Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 150.89K | -540.89K | -653.09K | -582.92K | -621.99K | -808.44K |
| EBITDA | -22.22M | -19.40M | -14.89M | -22.95M | -17.05M | -19.87M |
| Net Income | -27.96M | -22.45M | -15.55M | -23.53M | -17.68M | -20.74M |
Balance Sheet | ||||||
| Total Assets | 30.86M | 15.07M | 14.86M | 3.49M | 11.41M | 22.89M |
| Cash, Cash Equivalents and Short-Term Investments | 25.89M | 10.95M | 12.21M | 52.42K | 5.36M | 16.49M |
| Total Debt | 7.43M | 8.79M | 5.10M | 3.51M | 5.87M | 1.19M |
| Total Liabilities | 12.00M | 12.56M | 7.41M | 10.36M | 7.52M | 2.04M |
| Stockholders Equity | 18.86M | 2.51M | 7.46M | -6.87M | 3.88M | 20.84M |
Cash Flow | ||||||
| Free Cash Flow | -19.77M | -17.41M | -18.66M | -15.26M | -16.04M | -11.25M |
| Operating Cash Flow | -19.55M | -17.25M | -18.45M | -15.03M | -15.88M | -10.43M |
| Investing Cash Flow | -223.32K | -162.00K | -211.80K | -224.10K | -152.65K | -814.74K |
| Financing Cash Flow | 36.15M | 16.15M | 30.82M | 9.95M | 4.90M | 26.54M |
Cingulate Inc Technical Analysis
Negative
5.45
Price Trends
6.15
Negative
5.91
Negative
4.91
Negative
Market Momentum
-0.36
Positive
37.83
Neutral
15.24
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CING, the sentiment is Negative. The current price of 5.45 is above the 20-day moving average (MA) of 5.09, below the 50-day MA of 6.15, and above the 200-day MA of 4.91, indicating a bearish trend. The MACD of -0.36 indicates Positive momentum. The RSI at 37.83 is Neutral, neither overbought nor oversold. The STOCH value of 15.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CING.
Cingulate Inc Risk Analysis
Cingulate Inc disclosed 81 risk factors in its most recent earnings report. Cingulate Inc reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cingulate Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $31.96M | ― | -39.34% | ― | ― | 37.68% | |
48 Neutral | $5.50M | -6.93 | -226.28% | 10.27% | 10792.86% | 99.40% | |
47 Neutral | $60.67M | -1.63 | -368.38% | ― | ― | 58.01% | |
44 Neutral | $171.06M | <0.01 | 248.08% | ― | ― | ― | |
44 Neutral | $33.47M | -0.45 | -53.60% | ― | ― | 15.42% | |
42 Neutral | $5.47M | -0.15 | -1292.87% | ― | ― | -72.78% |
* Healthcare Sector Average
CING
Cingulate Inc
4.48
0.86
23.76%
BGMS
Bio Green Med Solution
0.97
-25.28
-96.30%
NNVC
NanoViricides
1.51
-0.05
-3.21%
ENLV
Enlivex
0.70
-0.29
-29.60%
FBLG
FibroBiologics, Inc.
1.09
-17.18
-94.03%
BOLD
Boundless Bio Inc.
1.42
-0.24
-14.46%
Cingulate Inc Corporate Events
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Cingulate Adds Independent Director Jiang to Board Committees
Positive
Apr 2, 2026
On March 27, 2026, Cingulate Inc. appointed Zhanpeng “Frederick” Jiang to its Board of Directors as a Class I director, with a term running until the 2028 annual stockholders’ meeting, subject to standard conditions. The appointm...
Private Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
Cingulate Announces ATM Equity Program and Share Issuance
Positive
Mar 24, 2026
On March 24, 2026, Cingulate Inc. entered into an at-the-market sales agreement with A.G.P./Alliance Global Partners, allowing the company to issue and sell up to $100 million of common stock from time to time under an existing shelf registration....
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
Cingulate Secures $12 Million PIPE to Advance CTx-1301
Positive
Feb 17, 2026
On February 6, 2026, Cingulate Inc. issued 25,786 common shares at $6.16 each to a lender in exchange for a portion of outstanding debt, using an exemption from registration to strengthen its balance sheet by partially reducing liabilities through...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.